Comparison
Deep 6 AI vs Mendel
Deep 6 AI and Mendel both used AI to read unstructured medical records, but for different jobs: Deep 6 AI matched a health system's patients to its clinical trials, while Mendel was a broader clinical data platform whose Hypercube copilots handled chart abstraction, chart review, cohort analysis and trial matching.[12],[15],[7],[3] Both have since joined larger companies: Tempus acquired Deep 6 AI on March 11, 2025, and Mendel's investor Oak HC/FT lists it as merged into Ensemble Health Partners.[11],[8] Neither publicly documented contacting matched patients. Bond Health finds patients in the EHR and then contacts, pre-screens and schedules them.[19]
Last updated Oct 23, 202620 sources
Partnered with
What is the difference between Deep 6 AI and Mendel?
- Focus. Deep 6 AI matched patients to a health system's investigator-initiated, government-funded and sponsored trials.[15] Mendel described itself as AI for "clinical data workflows" for providers, biopharma and diagnostics companies, and for providers offered prior authorization, chart review and trial matching.[1]
- Data. Deep 6 AI applied NLP to physician notes, lab, radiology and pathology reports, and genomics results.[16] Mendel's Hypercube abstracted the medical record "including unstructured data, such as genomic and pathology reports and clinical notes".[3]
- Connections. Deep 6 AI integrated with the health system's EMR.[16] Mendel's FAQ listed integrations with data warehouses such as Databricks and Snowflake and BI tools such as Tableau and Qlik; we found no EHR connector named in its materials.[5]
- Evidence. Deep 6 AI highlighted the patient data behind each criterion and showed the text where its NLP found each keyword.[17] Mendel said every answer was supported by evidence highlighted from the patient's original records.[4]
- Where each is now. Deep 6 AI's website said by January 2026 that it "is now a Tempus AI company".[18] Oak HC/FT lists Mendel as merged into Ensemble Health Partners, a Forbes Councils profile of an Ensemble executive dates the acquisition to July 2025, and Ensemble's Chief AI Officer, Wael Salloum, previously founded Mendel.ai.[8],[10],[9]
How do Deep 6 AI, Mendel and Bond compare, capability by capability?
Years in the Deep 6 AI and Mendel columns show each source's date. "Not publicly documented" means we found no public description in the materials we reviewed in October 2026, not that the capability never existed.
| Capability | Deep 6 AI (Tempus) | Mendel | Bond Health |
|---|---|---|---|
| Status in October 2026 | Part of Tempus since March 11, 2025. deep6.ai no longer loads; Tempus sells trial matching through TIME and Next Trials.[11],[18],[14] | Listed by its investor as merged into Ensemble Health Partners. mendel.ai did not load in September or October 2026.[8],[7] | Available to research sites, site networks, CROs and sponsors, with full EHR integration in 48 hours and no integration fee.[19] |
| Focus | Clinical trial matching across a health system's trials (2024).[15] | Clinical data platform: chart abstraction, chart review, cohort analysis, prior authorization and trial matching (2025).[1],[7] | Clinical trial recruitment, from EHR screening to outreach, booked visits and consent support, in any therapeutic area.[19],[20] |
| Trial matching | Mined real-time structured and unstructured EMR data to match patients to trials (2025).[12] | Found patients "from your system" who match a trial's inclusion and exclusion criteria, and mapped eligibility from protocol templates (2025).[2],[4] | LLM-based screening of the site's EHR against each protocol's criteria, returning ranked matches: 10,000+ charts per hour and 90%+ matching accuracy.[19] |
| Unstructured data | NLP over physician notes, lab, radiology and pathology reports, and genomics results (2023).[16] | Genomic and pathology reports and clinical notes (2025).[3] | Reads clinical notes, prescriptions and lab results, and uses imaging data and other unstructured documents, including pathology, radiology and molecular reports.[19],[20] |
| Evidence behind each answer | Highlighted the patient data related to each criterion and the text where its NLP found each keyword (2024).[17] | Every answer supported by evidence highlighted from the patient's original records (2025).[4] | Ranked matches come with the evidence behind each criterion decision and traceability to the chart.[19] |
| Data connections | Integrated with the health system's EMR (2023) and could bring in genomics, cancer registry and CTMS data (2024).[16],[17] | Data warehouses such as Databricks and Snowflake, and BI tools such as Tableau and Qlik (2025). No EHR connector named.[5] | Epic, Oracle Health (Cerner), MEDITECH, athenahealth, eClinicalWorks, NextGen, Veradigm, OncoEMR and the other major EHRs, plus CTMS systems including CRIO, Advarra OnCore, RealTime and Veeva SiteVault (implementation).[19],[20] |
| Patient outreach and scheduling | Not publicly documented (October 2026). | Not publicly documented (October 2026). | Voice and SMS agents contact matched patients, starting from what Identify found in the chart, and can pre-screen and book a visit in one conversation, in the patient's language.[19],[20] |
| Consent | Not publicly documented (October 2026). | Not publicly documented (October 2026). | Plain-language explanations, patient Q&A and staff escalation, with checks on the patient's understanding and an auditable record for the site. The site and PI obtain consent.[19],[20] |
| Who it served | Health systems, often through the Clinical Trials Office, and life sciences companies (2024).[15] | Providers, biopharma and diagnostics companies (2025), including life sciences customers (2024).[1],[6] | Any research site, including physician groups and FQHCs, plus site networks, CROs and sponsors.[19] |
| Pricing | No public price list found (October 2026). | Every product listed "Contact Sales" (2025).[2] | A volume-based fee per screened patient plus a percentage of the randomization milestone payment for each patient, with no integration fee (pricing).[20] |
What should you use instead of Deep 6 AI or Mendel?
- If you were evaluating Deep 6 AI, talk to Tempus about TIME and Next Trials, which pre-screen oncology patients for trials, and ask which Deep 6 AI capabilities it still offers.[13],[14]
- If you were evaluating Mendel for chart abstraction or cohort work, ask Ensemble Health Partners whether Mendel's products are still sold.[8]
- If you need patients enrolled, Bond finds them in your EHR, including clinical notes and pathology, radiology and molecular reports, then contacts, pre-screens and books them and supports consent, in any therapeutic area.[19],[20]
Why do sites choose Bond over EHR matching tools?
48 hours[19]
typical time to go live with full EHR integration, handled by Bond's team with no integration fee
10,000+[19]
charts screened per hour
Up to 3x[19]
faster enrollment than manual recruitment
- One product from chart to booked visit. Bond automates EHR screening, patient outreach, visit booking and consent tracking in one workflow, with "no data silos, no manual handoffs, and complete visibility from first ad click or chart match to a booked visit and signed consent."[19]
- Every ad lead contacted immediately, and followed up until they book. Bond creates and runs Meta and Google ad campaigns for each study. Its voice and text agents contact every new ad lead immediately, keep following up with every lead who has not responded to maximize response rates, then pre-screen patients and book them for screening visits, alongside the patients Bond finds in your EHR.[20]
- Every open study at once. Bond screens each patient against every open study at the site, so a patient who screens out of one study can be matched to another.[20]
- Support after enrollment. The same voice and SMS agents send visit reminders, book transportation, collect symptoms and diaries, run side-effect check-ins and flag participants at risk of dropping out.[20]
- Security you can check. Bond is HIPAA compliant and SOC 2 Type I compliant, and its information security management system is certified to ISO/IEC 27001:2022 by Advantage Partners. See security.[20]
How can you test a replacement on your own data?
- 1
Pick a study with a known answer
Use a closed or mature study where coordinators know who enrolled, who screen-failed and why.
- 2
Give each vendor the same protocol and patients
Same criteria, same records, under a business associate agreement. Ask for the chart evidence behind every criterion decision, not only a score.
- 3
Count what happens after the match
Track who contacts each matched patient, how fast, how many are reached and how many reach a screening visit.
- 4
Bring one protocol. We will show how Bond handles its hardest criteria, then how it contacts and books the patients it finds.
How was this comparison made?
Bond wrote this page in October 2026. mendel.ai did not load when we checked in September and October 2026, so Mendel facts come from Internet Archive copies of its website from June to August 2025, a 2024 Google Cloud article, a 2025 Meta article, its investor Oak HC/FT's portfolio page, Ensemble Health Partners' leadership page and a Forbes Councils profile. Deep 6 AI facts come from Tempus's 2025 Form 10-K, Deep 6 AI and Tempus press releases, Tempus web pages, an archived copy of Deep 6 AI's website and an Ohio State customer abstract. Bond's figures and capabilities come from its website and product information Bond provided. We used no private or internal competitive material.
Frequently asked questions
Is Mendel still available?
Who acquired Mendel?
Did Mendel do clinical trial matching?
Is Deep 6 AI part of Tempus?
Yes. Tempus's 2025 Form 10-K says it acquired Deep 6 AI, Inc. on March 11, 2025, and by January 2026 Deep 6 AI's website said it "is now a Tempus AI company".[11],[18] See Bond vs Tempus (Deep 6 AI).
What is an alternative to Deep 6 AI and Mendel?
Bond Health. It screens the EHR, including clinical notes and pathology, radiology and molecular reports, then contacts, pre-screens and schedules matched patients by voice and text and supports consent, in any therapeutic area.[19],[20] See Deep 6 AI vs Triomics for an oncology option.
Sources
- 1.Mendel homepage (archived) · Mendel, via the Internet Archive, 2025Internet Archive copy of August 30, 2025, read October 23, 2026. Quotes: "Supercharge your clinical data workflows. AI copilots that can clinically reason"; "Whether you're in clinical care, pharmaceuticals, or diagnostics, our solutions are designed to meet your specific needs."; "For Providers Streamline prior authorizations, enhance chart review accuracy, and efficiently match patients to clinical trials."
- 2.Mendel for providers (archived) · Mendel, via the Internet Archive, 2025Internet Archive copy of June 21, 2025, read October 23, 2026. Quotes: "Trial Matching Find patients from your system who match the inclusion and exclusion criteria of trials being recruited for."; "Mendel helps physicians and care coordinators to chat with the structured and unstructured EMR data". Each product card reads "Pricing Contact Sales".
- 3.Clinical data abstraction one-sheet (archived) · Mendel, via the Internet Archive, 2025Internet Archive copy of July 12, 2025, read October 23, 2026. Quote: "Hypercube is your AI copilot, powering comprehensive abstraction of the medical record including unstructured data, such as genomic and pathology reports and clinical notes."
- 4.Hypercube Charts (archived) · Mendel, via the Internet Archive, 2025Internet Archive copy of July 12, 2025, read October 23, 2026. Quotes: "Craft a template incorporating prior-authorization criteria, NCCN guidelines, and trial protocols, and Hypercube will seamlessly map patient eligibility."; "Every answer is supported by discrete evidence highlighted from the patient's original records".
- 5.Mendel FAQ (archived) · Mendel, via the Internet Archive, 2025Internet Archive copy of August 28, 2025, read October 23, 2026. Quote: "Integrations with your current data warehouse such as Databricks and Snowflake, most BI tools like Tableau, Qlik, etc."
- 6.Can gen AI bring order to medical records? This startup is giving it a shot. · Google Cloud Blog (Transform), 2024Published July 25, 2024, by Sumeet Ranu and Matt A.V. Chaban; re-checked October 23, 2026. Quotes: Mendel has "some of the world's leading life sciences companies as customers"; Hypercube Charts: "Chat with medical records through a user-friendly interface with sophisticated clinical reasoning to complete chart reviews for visits, pre-authorization, trial matching and more".
- 7.Dramatically accelerating patient-matching in clinical trials with open source · Meta AI (blog), 2025Published February 19, 2025, re-checked October 23, 2026. Quotes: "Mendel Hypercube, tackles clinical tasks like data abstraction, chart reviews, and patient cohort analysis." and "With Llama, Hypercube can also be used to chat and query in natural language for trial matching and putting together patient groups." Mendel's own website did not load when we checked in September and October 2026.
- 8.Mendel portfolio page · Oak HC/FT, 2026Read October 23, 2026. The page describes Mendel as a "Clinical data extraction and processing platform" with the status "Merged: Ensemble Health Partners".
- 9.Leadership · Ensemble Health Partners, 2026Read October 23, 2026. Quote, on Chief AI Officer Wael Salloum: "He previously founded Mendel.ai, a clinical AI platform advancing data workflows through large language models".
- 10.Pradeep Prasana Kanagaraj, VP, AI Operations & Transformation, Ensemble Health Partners · Forbes Technology Council member profileUndated member profile, read October 23, 2026. Its company bio reads: "Mendel.ai was acquired by Ensemble Health Partners in July 2025." We found no press release from either company.
- 11.Tempus AI, Inc. Form 10-K for fiscal year ended December 31, 2025 · Tempus AI, Inc. / U.S. Securities and Exchange Commission, 2026Filed February 2026, accessed September 2026. Quote: "On March 11, 2025, the Company acquired all of the issued and outstanding interests of Deep 6 AI, Inc." Revenue: "The Company's Trials product includes TIME clinical trial matching services and other clinical trial services"; "To the extent the contract requires, the Company may also assist in opening the clinical trial site and enrolling the patient in the clinical trial"; "depending on the type of agreement"; "revenue is recognized upon one of the following: delivery of a notification to the physician alerting them to a clinical trial match, or once a patient is enrolled in a trial"; "the customer, which is the clinical trial sponsor". Data connections: "We use a variety of near real-time connections (e.g., HL7, FHIR) and batch data exchanges"; "Our proprietary tools connect to a provider's EHR system, data warehouse, or third-party data provider to pull out relevant structured and unstructured data that the provider has agreed to provide to Tempus"; "In certain circumstances, we cover the actual direct costs associated with the technical integrations needed to create a data connection."
- 12.Tempus Announces Acquisition of Deep 6 AI · Tempus AI, Inc. press release, 2025Press release dated March 11, 2025, read October 23, 2026. Quotes: "today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies" and "Its AI-powered software matches patients to clinical trials by mining real-time structured and unstructured electronic medical record (EMR) data".
- 13.Clinical Trial Matching for Oncology | TIME Trial Network · Tempus AI, Inc. (tempus.com), 2026Re-checked on tempus.com October 23, 2026. Quote: trial matching "with a clinical team of experts pre-screening the matched patients and presenting potentially eligible patients with a white-glove service to each site" and, under enhanced patient pre-screening, "Generative AI scans structured and unstructured clinical notes, enhancing identification of patients who may be eligible for trial participation."
- 14.Tempus Next Trials · Tempus AI, Inc. (tempus.com), 2026Read October 23, 2026. Quotes: "AI-enabled platform supports clinical trial pre-screening based on your patients' multimodal, structured and unstructured health information (clinical, imaging and molecular data)"; "Accelerate accrual to trials already open at your practice"; "AI-enhanced workflows are designed to assist site clinicians in identifying, screening and enrolling eligible patients for TIME trials."; "When ready, Next Trials can be expanded to pre-screen patients across additional disease groups beyond oncology."
- 15.Doug Cassidy Appointed President of the Deep 6 AI Precision Research Ecosystem · Deep 6 AI (PR Newswire), 2024Company press release, July 24, 2024. Quote: "Healthcare organizations that become part of the Ecosystem use the company's AI-powered software platform enterprise-wide for investigator-initiated, government-funded, and sponsored trials. Often, the technology is managed centrally (i.e., by the Clinical Trials Office)" and "the launch of our life sciences vertical in 2021".
- 16.Texas Tech University Health Sciences Center Partners with Deep 6 AI to Launch an AI Program for Clinical Trials · Deep 6 AI (PR Newswire), 2023Company press release, August 1, 2023. Quote: Deep 6 AI uses natural language processing to search "structured and unstructured EMR data points, such as physician notes, lab reports, outpatient notes, radiology reports, genomics results, and pathology reports" and "By integrating with TTUHSC's EMR, Deep 6 AI's software platform can precision-match patients to trials".
- 17.Integrating AI-Enabled Clinical Trial Matching into Operations · Stillman R, Campbell A, Humphries K, Schweitzer C. The Ohio State University Comprehensive Cancer Center; AACI CRI 2024 abstract, 2024Customer work-in-progress abstract on Deep 6 AI at Ohio State, accessed September 2026. Quote: "a user interface that speeds patient screening by presenting and highlighting patient data related to the inclusion/exclusion criteria across a longitudinal patient record"; "to be able to reference the text in which the NLP identified the keywords to view the keywords in context to confirm the finding"; "Deep 6 AI can incorporate multiple data sources beyond the electronic medical records (EMR), such as genomics, custom databases, cancer registries, CTMS, etc."
- 18.Deep 6 AI homepage (archived) · Deep 6 AI, via the Internet Archive, 2026Internet Archive copy of January 3, 2026. Quotes: "Deep 6 AI has joined Tempus." and "Deep 6 AI is now a Tempus AI company". deep6.ai itself did not load when we checked on October 23, 2026.
- 19.Bond Health: platform overview, FAQ and pricing · Bond Health, 2026
- 20.Bond Health product information · Bond Health, 2026Capabilities, pricing and compliance status described by Bond Health, October 2026.
Related pages
Deep 6 AI vs Triomics
General EHR matching vs an oncology platform.
ReadDeep 6 AI vs Paradigm Health
Matching software vs a sponsor-funded research network.
ReadBond vs Tempus (Deep 6 AI)
Deep 6 AI, TIME and Next Trials, compared with Bond.
ReadPricing
No integration fee: a volume-based fee per screened patient plus a percentage of the randomization milestone payment for each patient.
ReadSecurity
How Bond handles PHI, BAAs and audit logging.
ReadIdentify: LLM-based EHR screening
How Bond reads the chart and explains each match.
Read